Nasalferon, a new nasal formulation of IFNα2b, modulates cellular and molecular elements associated with an antiviral response in mucosa and blood
Dania Vázquez‐Blomquist(Centro de Ingeniería Genética y Biotecnología), Gerardo Guillén(Hunan City University), Iris Valdés(Centro de Ingeniería Genética y Biotecnología), Isabel Gonzáles Moya(Centro de Ingeniería Genética y Biotecnología), Yssel Mendoza‐Marí(Western University of Health Sciences), Giselle Freyre Corrales(Centro de Ingeniería Genética y Biotecnología), Ricardo Martínez Rosales(Centro de Ingeniería Genética y Biotecnología), Mónica Béquet‐Romero(Centro de Ingeniería Genética y Biotecnología), Gilda Lemos(Centro de Ingeniería Genética y Biotecnología), Camila Canaán-Haden Ayala(Centro de Ingeniería Genética y Biotecnología)
Cited by 5
Related Papers
Epidermal growth factor in clinical practice – a review of its biological actions, clinical indications and safety implications
|International Wound Journal|2009|167
A novel cancer vaccine composed of human-recombinant epidermal growth factor linked to a carrier protein: Report of a pilot clinical trial
|Annals of Oncology|1998|155
Glucose Toxic Effects on Granulation Tissue Productive Cells: The Diabetics’ Impaired Healing
|BioMed Research International|2012|153
Wound Chronicity, Impaired Immunity and Infection in Diabetic Patients
|MEDICC Review|2021|139
Insulin Resistance at the Crossroad of Alzheimer Disease Pathology: A Review
|Frontiers in Endocrinology|2020|134